Bevacizumab Overview

Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. It is used in the treatment of cancer, where it inhibits tumor growth by blocking the formation of new blood vessels. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States. Bevacizumab was approved by the U.S. Food and Drug Administration in 2004 for use in combination with standard chemotherapy in the treatment of metastatic colon cancer and...